Reagent for detecting multiple myeloma characteristic protein by mass spectrum
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0075] Example 1 The distinction between normal and multiple myeloma patients and the preparation of mass spectrometry kits
[0076] (1) Experimental method
[0077] A total of 54 consecutive patients with multiple myeloma (37 males and 17 females) were used in this study. Their average age was 58 (range 46 to 83). 25 patients were newly diagnosed, according to the Durie / Salmon staging system, 7 of them were multiple myeloma stage II, 18 were stage III, 29 underwent chemotherapy after blood samples were collected (6 achieved complete remission , 13 partial responses, 5 relapses, and 5 other conditions). Among the 29 patients who underwent chemotherapy, 13 were selected for the second chemotherapy after 2 or 3 sampling chemotherapy. Blood samples from these patients were collected from serum. 108 non-multiple myeloma control serum samples from healthy volunteers (n=62) or patients with other diseases that must be differentiated from multiple myeloma (POEMS syndrome, n=4); N...
Embodiment 2
[0097] Embodiment 2 clinical trial and double-blind test;
[0098] Since the combination of multiple characteristic proteins can completely separate multiple myeloma from normal people, any two or more of the above-mentioned 56 characteristic proteins are selected, and according to the mass-to-charge ratio m / Based on the z value and the critical peak value M of the protein, patients with multiple myeloma were identified from normal people and multiple myeloma (POEMS syndrome; NHL; MGUS; CRF; rheumatism; macroglobulinemia ; or other tumors with bone metastases) two-to-two identification of serum signature protein detection mass spectrometry model ( figure 1-5), said specific protein mass-to-charge ratio m / z and critical peak value M are respectively m / z=8139, M≤5.88; m / z=11682, M≤0.78; m / z=22778, M≤ 0.64 ((The upper part of Figure 2(a), (b), (c) is the calibration map representing MM (marked as MM1 and MM2); the middle part of Figure 2(a), (b), (c) is the non- MM control [di...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com